The Developmental History of the Gadolinium Chelates as Intravenous Contrast Media for Magnetic Resonance

@article{Runge2011TheDH,
  title={The Developmental History of the Gadolinium Chelates as Intravenous Contrast Media for Magnetic Resonance},
  author={Val Murray Runge and Tao Ai and Dapeng Hao and Xuemei Hu},
  journal={Investigative Radiology},
  year={2011},
  volume={46},
  pages={807–816}
}
The developmental history of the gadolinium chelates, which spans 30 years, is described, focusing, in part, on the seminal work with each of the major agents in use today. By examining this history, insight is gained into important issues of efficacy and safety, with valuable lessons to be learned from the mistakes made during this period. An overview of physicochemical characteristics and chemical structures is also provided. The review concludes with a discussion of current research… Expand
Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus
  • V. Runge
  • Medicine
  • Investigative radiology
  • 2016
TLDR
This review discusses first the background in terms of development of these agents and safety discussions therein, and second their relative stability based both on in vitro studies and clinical observations before and including the advent of nephrogenic systemic fibrosis. Expand
The Use of Gadolinium in Musculoskeletal MRI—Time to Rethink?
Magnetic resonance imaging has continued to evolve over the recent decades, in part, due to the evolution of gadolinium-based contrast agents and their use. These were initially thought to have aExpand
Gadolinium deposition and the potential for toxicological sequelae – A literature review of issues surrounding gadolinium‐based contrast agents
TLDR
This review will address some of the controversies surrounding the safety of GBCA administration based on evidence from in vivo experiments, animal studies and clinical studies, and discuss whether gadolinium deposition disease exists as a new diagnosis. Expand
Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic Resonance
TLDR
Development of such next-generation agents with a substantial improvement in relaxivity, in comparison with the current group of approved agents, with a 2-fold increase likely achievable, could lead to improved lesion enhancement, characterization, diagnosis, and, thus, clinical efficacy. Expand
Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents
TLDR
There is no evidence to-date that gadolinium retention leads to any disease or disorders in subjects with normal renal function, and the FDA did not restrict GBCA use, but will continue to study their safety and urged clinicians to use these agents sparingly. Expand
Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan)
  • V. Runge
  • Medicine
  • Investigative radiology
  • 2018
TLDR
Of particular concern would be nephrogenic systemic fibrosis–like symptoms—including particularly pain and skin/joint symptoms, or disease related to the incorporation of gadolinium in hydroxyapatite in bone, in small subgroups of patients with a not yet defined propensity and/or cofactor. Expand
Gadolinium-based contrast agents in neurofibromatosis type 1 (Review)
TLDR
The screening of the brain with magnetic resonance (MR) imaging is utilised to evaluate the patients with neurofibromatosis type 1 and as an aid in the diagnosis of asymptomatic patients when clinical criteria are not met. Expand
Imaging With Lanthanides
Materials based on cations of the lanthanide series have found widespread use as contrast agents (CAs) in most of the biomedical imaging techniques. In this chapter we give a review of the mainExpand
Recent Advances in Bifunctional Paramagnetic Chelates for MRI
Magnetic resonance imaging (MRI) is a non-invasive diagnostic modality routinely employed in modern clinical medicine to collect images of the internal organs of the human body. Contrast agents (CA)Expand
Historical Perspective of Imaging Contrast Agents.
TLDR
Iodine-based intravascular agents became the radiographic compounds of choice and refinements of their chemical structures led to the highly tolerated low-osmolarity agents in use today. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 163 REFERENCES
Notes on "Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent".
  • V. Runge
  • Medicine
  • AJR. American journal of roentgenology
  • 2008
TLDR
It is concluded that “the combination of strong proton relaxation, in vivo stability, rapid urinary excretion, and high tolerance favors the further development and the potential clinical application of gadolinium– DTPA as a contrast enhancer in MRI”. Expand
Extracellular gadolinium-based contrast media: an overview.
TLDR
This review describes the current status of gadolinium-CA, their mechanism of action, chemical structure, pharmacokinetics, dosage, elimination, nephrotoxicity and adverse events. Expand
Magnetic resonance contrast agents in neuroimaging. New agents and applications.
TLDR
The nonionic character of the two newer MR contrast agents is not of great importance in current clinical practice, in which most examinations are still performed with a dose of 0.1 mmol/kg given as a slow infusion, but the non-ionic nature of the newer MR Contrast agents may become clinically important in the future. Expand
The use of gadolinium-BOPTA on magnetic resonance imaging in brain infection.
TLDR
In intraparenchymal brain infection, Gd-BOPTA provides effective lesion enhancement when used at a dose of 0.1 mmol/kg. Expand
Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent.
TLDR
The combination of strong proton relaxation, in-vivo stability, rapid urinary excretion, and high tolerance favors the further development and the potential clinical application of gadolinium-DTPA as a contrast enhancer in magnetic resonance imaging. Expand
Initial clinical evaluation of gadolinium DTPA for contrast-enhanced magnetic resonance imaging.
TLDR
Gadolinium DTPA was evaluated as an intravenous contrast agent for magnetic resonance imaging in 15 patients with primary or secondary intracranial neoplastic disease and showed similar in magnitude to the contrast enhancement observed on CT. Expand
A Review of Preclinical Safety Data for Magnevist (Gadopentetate Dimeglumine) in the Context of Nephrogenic Systemic Fibrosis
TLDR
Preclinical safety data from in vivo studies in healthy rats and dogs conducted with Magnevist during the drug development process in the mid-80s were reassessed to analyze whether the acquired knowledge on NSF would lead to a revised interpretation of the original preclinical data. Expand
Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review
TLDR
A high kinetic stability provided by the macrocyclic structure combined with a high thermodynamic stability (reinforced by ionicity for macro cyclic chelates) will minimize the amount of free gadolinium released in tissue parenchymas. Expand
The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption.
TLDR
The ability to detect an alteration of the BBB, when present without associated edema, has been demonstrated with the application of control enhancement, and the use of contrast agents in MRI will enhance both the sensitivity and specificity of magnetic resonance imaging. Expand
Cardiovascular Safety of Gadoterate Meglumine (Gd-DOTA)
TLDR
These results confirmed the good safety profile of Gd-DOTA derived from postmarketing evaluations and confirmed that nonspecific gadolinium complexes used for magnetic resonance contrast enhancement do not constitute a class-at-risk for drug-related arrhythmias. Expand
...
1
2
3
4
5
...